Single-inhaler Triple Therapy Utilizing the Once-daily Combination of Fluticasone Furoate, Umeclidinium and Vilanterol in the Management of COPD: the Current Evidence Base and Future Prospects

Overview

Journal Ther Adv Respir Dis

Publisher Sage Publications

Specialties Pharmacology
Pulmonary Medicine

Date 2018 Mar 15

PMID 29537340

Citations 6

Authors

Mario Malerba

Matteo Nardin

Giuseppe Santini

Nadia Mores

Alessandro Radaeli

Paolo Montuschi

Affiliations

Soon will be listed here.

Abstract

Maintenance pharmacological treatment for stable chronic obstructive pulmonary disease (COPD) is based on inhaled drugs, including long-acting muscarinic receptor antagonists (LAMA), long-acting β-adrenoceptor agonists (LABA) and inhaled corticosteroids (ICS). Inhaled pharmacological treatment can improve patients' daily symptoms and reduce decline of pulmonary function and acute exacerbation rate. Treatment with all three inhaled drug classes is reserved for selected, more severe, patients with COPD when symptoms are not sufficiently controlled by dual LABA/LAMA therapy and exacerbations are frequent. This review focuses on the role of single-inhaler triple therapy with once-daily fluticasone furoate/umeclidinium/vilanterol fixed-dose combination, which is in phase III clinical development for maintenance treatment of severe-to-very severe COPD. In this review, we summarize evidence providing the rationale for its use in COPD and discuss the gaps to be filled in this pharmacotherapeutic area.

Citing Articles

Clinical Concepts for Triple Therapy Use in Patients with COPD: A Delphi Consensus.

Miravitlles M, Acharya S, Aggarwal B, Fernandes F, Dreyse J, Jardim J Int J Chron Obstruct Pulmon Dis. 2023; 18:1853-1866.

PMID: 37662490 PMC: 10474219. DOI: 10.2147/COPD.S424128.

Comparative efficacy of single-inhaler triple therapies for COPD: A protocol for systematic review and network meta-analysis.

Jiang Y, Hu H, Leung S PLoS One. 2021; 16(8):e0255545.

PMID: 34351996 PMC: 8341520. DOI: 10.1371/journal.pone.0255545.

Prescribing pathways to triple therapy in patients with chronic obstructive pulmonary disease in the United States.

Schabert V, Shah S, Holmgren U, Cabrera C Ther Adv Respir Dis. 2021; 15:17534666211001018.

PMID: 33866875 PMC: 8058794. DOI: 10.1177/17534666211001018.

A Delphi Consensus Document on the Use of Single-Inhaler Fixed-Dose Triple Therapies in COPD Patients.

Lopez-Campos J, Navarrete B, Riesco Miranda J, Cosio B, de-Torres J, Celli B Int J Chron Obstruct Pulmon Dis. 2020; 15:1801-1811.

PMID: 32884252 PMC: 7435744. DOI: 10.2147/COPD.S258818.

Triple therapy in the management of chronic obstructive pulmonary disease: systematic review and meta-analysis.

Zheng Y, Zhu J, Liu Y, Lai W, Lin C, Qiu K BMJ. 2018; 363:k4388.

PMID: 30401700 PMC: 6218838. DOI: 10.1136/bmj.k4388.

References

Tashkin D, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S . A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008; 359(15):1543-54. DOI: 10.1056/NEJMoa0805800. View

Ismaila A, Birk R, Shah D, Zhang S, Brealey N, Risebrough N . Once-Daily Triple Therapy in Patients with Advanced COPD: Healthcare Resource Utilization Data and Associated Costs from the FULFIL Trial. Adv Ther. 2017; 34(9):2163-2172. PMC: 5599456. DOI: 10.1007/s12325-017-0604-x. View

Belmonte K . Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005; 2(4):297-304. DOI: 10.1513/pats.200504-043SR. View

Jiang Z, Zhu L . Update on molecular mechanisms of corticosteroid resistance in chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2016; 37:1-8. DOI: 10.1016/j.pupt.2016.01.002. View

Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, Watz H, Tetzlaff K . Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014; 371(14):1285-94. DOI: 10.1056/NEJMoa1407154. View

Disse B, Speck G, ROMINGER K, Witek Jr T, Hammer R . Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci. 1999; 64(6-7):457-64. DOI: 10.1016/s0024-3205(98)00588-8. View

Montuschi P, Ciabattoni G . Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends. J Med Chem. 2015; 58(10):4131-64. DOI: 10.1021/jm5013227. View

Wang M, Liou J, Lin C, Tsai C, Wang Y, Hsu Y . Association of Cardiovascular Risk With Inhaled Long-Acting Bronchodilators in Patients With Chronic Obstructive Pulmonary Disease: A Nested Case-Control Study. JAMA Intern Med. 2018; 178(2):229-238. PMC: 5838614. DOI: 10.1001/jamainternmed.2017.7720. View

Barnes P . Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2013; 131(3):636-45. DOI: 10.1016/j.jaci.2012.12.1564. View

10.

Aaron S, Vandemheen K, Fergusson D, Maltais F, Bourbeau J, Goldstein R . Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007; 146(8):545-55. DOI: 10.7326/0003-4819-146-8-200704170-00152. View

11.

Rojas-Reyes M, Garcia Morales O, Dennis R, Karner C . Combination inhaled steroid and long-acting beta₂-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2016; (6):CD008532. PMC: 6481546. DOI: 10.1002/14651858.CD008532.pub3. View

12.

Brusselle G, Price D, Gruffydd-Jones K, Miravitlles M, Keininger D, Stewart R . The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int J Chron Obstruct Pulmon Dis. 2015; 10:2207-17. PMC: 4621207. DOI: 10.2147/COPD.S91694. View

13.

Pascoe S, Locantore N, Dransfield M, Barnes N, Pavord I . Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015; 3(6):435-42. DOI: 10.1016/S2213-2600(15)00106-X. View

14.

Calverley P, Anderson J, Brook R, Crim C, Gallot N, Kilbride S . Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. Am J Respir Crit Care Med. 2017; 197(1):47-55. DOI: 10.1164/rccm.201610-2086OC. View

15.

Pera T, Penn R . Crosstalk between beta-2-adrenoceptor and muscarinic acetylcholine receptors in the airway. Curr Opin Pharmacol. 2014; 16:72-81. PMC: 4096844. DOI: 10.1016/j.coph.2014.03.005. View

16.

Hanania N, Feldman G, Zachgo W, Shim J, Crim C, Sanford L . The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest. 2012; 142(1):119-127. DOI: 10.1378/chest.11-2231. View

17.

Malerba M, Radaeli A, Montuschi P, Morjaria J . Vilanterol trifenatate for the treatment of COPD. Expert Rev Respir Med. 2016; 10(7):719-31. DOI: 10.1080/17476348.2016.1184976. View

18.

Liu Y, Shi H, Sun X, Zhang D, Zhang Y, Yang K . Benefits of adding fluticasone propionate/salmeterol to tiotropium in COPD: a meta-analysis. Eur J Intern Med. 2014; 25(5):491-5. DOI: 10.1016/j.ejim.2014.04.007. View

19.

Wedzicha J, Banerji D, Chapman K, Vestbo J, Roche N, Ayers R . Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016; 374(23):2222-34. DOI: 10.1056/NEJMoa1516385. View

20.

Lee S, Xie C, Yunus F, Itoh Y, Ling X, Yu W . Efficacy and tolerability of budesonide/formoterol added to tiotropium compared with tiotropium alone in patients with severe or very severe COPD: A randomized, multicentre study in East Asia. Respirology. 2015; 21(1):119-27. DOI: 10.1111/resp.12646. View